Share

Health Economics & Outcomes Research

With increasing pressure to control the rising cost of healthcare, there’s a greater need to demonstrate the value of health care treatments in addition to their efficacy. HEOR analytics plays an increasingly vital role in a drug’s approval and reimbursement with payers. HEOR analyses allow us to evaluate the economics of a given treatment and quantify the associated outcomes.

Key Offerings

sales-analytics-icon5

Patient-Level
Simulation

​​Test and analyze complex treatment outcomes on various types of patients with our patient-level simulations, supported with real world and clinical trials data.

sales-analytics-icon6

Cost Effectiveness
Models

Ensure cost-effectiveness to maximize chances of drug approval, with our customized and analytically rigorous models. These models are transparent and adaptable for global stakeholders.

sales-analytics-icon7

Clinical Trial
Simulations

Make informed decisions around clinical trial design with Axtria’s trial simulations. Ensure cost-effective analyses and reduced iterations across varying scenarios for continued product benefits. ​

sales-analytics-icon2

Burden of Disease
Analysis

Get detailed insights into the cost, morbidity, mortality and unmet needs associated with multiple treatment options, to maximize patient well-being and cost-effectiveness

sales-analytics-icon3

Real World Data
Experience

Experience real-world evidence-based insights, using real-world and anonymized patient-level data to make educated decisions on various treatment options and their implied outcomes.

sales-analytics-icon4

Managed Markets and
HEOR Analytics

Unveil market complexities with Axtria’s deep domain and strategy consulting expertise in managed markets, and hands-on experience with traditional and emerging datasets in this space.

Customer Success Stories

Explore How Axtria Helps Life Sciences Businesses Achieve Commercial Success.

Data & Analytics Center Of Excellence (CoE) For A Global Pharma

Life sciences organizations are struggling with several factors, including fragmented analytics teams, siloed decision making, limited thought leadership, and inflexible operating ...

Strategic Course Correction For A Blockbuster Oncology Drug

A top pharma company that had done well to grow their oncology drug to a blockbuster status was struggling with understanding and achieving its full potential. Axtria provided str ...

Sales Force Restructuring Strategy For A New Oncology Indication Launch In The US

With the rise of specialty pharma, the interactions between sales reps and healthcare stakeholders are becoming more profound, more productive, and much more scientific. ...